Improved survival in metastatic breast cancer 1985–2016

Breast

Volumn 31, Issue , 2017, Pages 46-50

  Sundquist, Marie ^a   Brudin, Lars ^a   Tejler, Göran ^b  

^a KALMAR COUNTY HOSPITAL   (Sweden)

^b Västervik Hospital   (Sweden)

Author keywords

Breast cancer; Metastatic; Prognosis; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; PRIORITY JOURNAL; SURVIVAL TIME; SWEDEN; TREND STUDY; AGED; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; REGISTER; SURVIVAL RATE; TRENDS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; REGISTRIES; SURVIVAL RATE; SWEDEN; TRASTUZUMAB;

EID: 84994005691     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2016.10.005     Document Type: Article

References (38)

1. [1] Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. Lancet 379:9814 (4–10 February 2012), 432–444.
2. [2] Brenner, H., Hakulinen, T., Are patients diagnosed with breast cancer before age 50 years ever cured?. J Clin Oncol 22:3 (2004), 432–438.
3. [3] Garne, J.P., Cure in Breast Cancer following treatment for distant metastases. Invasive breast Cancer Malmö 1961-1992. Malmö: Thesis, 1996, 158–173.
4. [4] van Tienhoven, G., Voogd, A.C., Peterse, J.L., Nielsen, M., Andersen, K.W., Mignolet, et al. Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group. Eur J Cancer 35:1 (1999), 32–38.
5. [5] Buchanan, C.L., Dorn, P.L., Fey, J., Giron, G., Naik, A., Mendez, J., et al. Locoregional recurrence after mastectomy: incidence and outcomes. J Am Coll Surg 203:4 (2006), 469–474.
6. [6] Schmoor, C., Sauerbrei, W., Bastert, G., Schumacher, M., Role of isolated locoregional recurrence of breast cancer: results of four prospective studies. J Clin Oncol 18:8 (2000), 1696–1708.
7. [7] Alanko, A., Heinonen, E., Scheinin, T.M., Tolppanen, E.M., Vihko, R., Oestrogen and progesterone receptors and disease-free interval in primary breast cancer. Br J Cancer 50:5 (1984), 667–672.
8. [8] Jubelirer, S.J., Wilson, R., Summers, L., Richardson, S., Prognostic factors determining survival in breast cancer patients presenting with metastatic disease. W V Med J 86:1 (1990), 7–9.
9. [9] Shek, L.L., Godolphin, W., Spinelli, J.J., Oestrogen receptors, nodes and stage as predictors of post-recurrence survival in 457 breast cancer patients. Br J Cancer 56:6 (1987), 825–829.
10. [10] Clark, G.M., Sledge, G.W., Osborne, C.K., McGuire, W.L., Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 5:1 (1987), 55–61.
11. [11] Alexieva-Figusch, J., Van Putten, W.L., van Gilse, H.A., Blonk-vd Wijst, J., Klijn, J.G., Sequential treatment of metastatic breast cancer with tamoxifen after megestrol acetate therapy and vice versa (a retrospective study). Med Oncol Tumor Pharmacother 2:2 (1985), 69–75.
12. [12] Stål, O., Carstensen, J.M., Wingren, S., Rutqvist, L.E., Skoog, L., Klintenberg, C., et al. Relationship of DNA ploidy and S-phase fraction to survival after first recurrence of breast cancer. Acta Oncol 33:4 (1994), 423–429.
13. [13] Hatschek, T., Carstensen, J., Fagerberg, G., Stål, O., Gröntoft, O., Nordenskjöld, B., Influence of S-phase fraction on metastatic pattern and post-recurrence survival in a randomized mammography screening trial. Breast Cancer Res Treat 14:3 (1989), 321–327.
14. [14] Hietanen, P., Miettinen, M., Mäkinen, J., Survival after first recurrence in breast cancer. Eur J Cancer Clin Oncol 22:8 (1986), 913–919.
15. [15] Blanco, G., Holli, K., Heikkinen, M., Kallioniemi, O.P., Taskinen, P., Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading. Br J Cancer 62:1 (1990), 142–146.
16. [16] Pater, J.L., Mores, D., Loeb, M., Survival after recurrence of breast cancer. Can Med Assoc J 124:12 (1981), 1591–1595.
17. [17] Horiguchi, J., Iino, Y., Takei, H., Maemura, M., Takeyoshi, I., Yokoe, T., et al. c-erbB-2 status is an independent predictor of survival after first recurrence. Int J Oncol 12:1 (1998), 123–128.
18. [18] Elston, C.W., Ellis, I.O., Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 41:3A (2002), 154–161.
19. [19] Sundquist, M., Thorstenson, S., Brudin, L., Nordenskjold, B., South east Swedish breast Cancer study group applying the Nottingham prognostic index to a Swedish breast cancer population. Breast Cancer Res Treat 53:1 (1999 Jan), 1–8.
20. [20] Blamey, R.W., Hornmark-Stenstam, B., Ball, G., Blichert-Toft, M., Cataliotti, L., Fourquet, A., et al. Ellis I ONCOPOOL – a European database for 16,944 cases of breast cancer. Eur J Cancer 46:1 (January 2010), 56–71.
21. [21] Wrange, O., Nordenskjold, B., Silfversward, C., Granberg, P.O., Gustafsson, J.A., Isoelectric focusing of estradiol receptor protein from human mammary carcinoma - a comparison to sucrose gradient analysis. Eur J Cancer 12 (1976), 695–700.
22. [22] Wrange, O., Nordenskjold, B., Gustafsson, J.A., Cytosol estradiol receptor in human mammary carcinoma: an assay based on isoelectric focusing in polyacrylamide gel. Anal Biochem 85 (1978), 461–475.
23. [23] Ferno, M., Borg, A., Sellberg, G., Enzyme immuno assay of the estrogen receptor in breast cancer biopsy samples. A comparison with isoelectric focusing. Acta Radiol Oncol 25 (1986), 171–175.
24. [24] Ferno, M., Borg, A., Norgren, A., A comparison of two steroid receptor assays in breast cancer: dextran coated charcoal and isoelectric focusing. Anticancer Res 3 (1983), 243–246.
25. [25] Burton, K., A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J 62 (1956), 315–323.
26. [26] Grabau, G.A., Bendahl, P.O., Rydén, L., Stål, O., Fernö M for the South and South-East Swedish Breast Cancer groups. The prevalence of immunohistochemically determined oestrogen receptor positivity in primary breast cancer is dependent on the choice of antibody and method of heat-induced epitope retrieval – prognostic implications?. Acta Oncol 52 (2013), 1657–1666.
27. [27] Kaplan, E.L., Meijer, P., Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958), 457–481.
28. [28] Cox, D.R., Regression models and life tables. J R Stat Soc Ser B Methodol 34 (1972), 187–220.
29. [29] Stat, S.I., Computer program manual. 1995, Stat Soft, inc, Tulsa OK.
30. [30] Powles, T.J., Coombes, R.C., Smith, I.E., Jones, J.M., Ford, H.T., Gazet, J.C., Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet 1:8168 PT 1 (1980), 580–582.
31. [31] Patel, J.K., Nemoto, T., Vezeridis, M., Petrelli, N., Suh, O., Dao, T.L., Does more intense palliative treatment improve overall survival in metastatic breast cancer patients?. Cancer 57:3 (1986), 567–570.
32. [32] Patanaphan, V., Salazar, O.M., Poussin-Rosillo, H., Prognosticators in recurrent breast cancer. A 15-year experience with irradiation. Cancer 54:2 (1984), 228–234.
33. [33] Debonis, D., Terz, J.J., Eldar, S., Hill, L.R., Survival of patients with metastatic breast cancer diagnosed between 1955 and 1980. J Surg Oncol 48:3 (1991), 158–163.
34. [34] Giordano, S.H., Buzdar, A.U., Smith, T.L., Kau, S.W., Yang, Y., Hortobagyi, G.N., Is breast cancer survival improving?. Cancer 100:1 (2004), 44–52.
35. [35] Tevaarwerk, A.J., Gray, R., Schneider, B.P., Smith, M.L., Wagner, L.I., Fetting, J.H., et al. Survival in patients with metastatic recurrent breast Cancer after adjuvant chemotherapy little evidence of improvement over the past 30 years. Cancer, March 15, 2013, 1140–1148.
36. [36] Giuliani, J., Bonetti, A., Trends in survival for patients with metastatic breast cancer: is survival improving?. Tumori 101:4 (2015), 347–352.
37. [37] Weide, R., Feiten, S., Friesenhahn, V., Heymanns, J., Kleboth, K., Thomalla, J., et al. Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor and Her2-positive tumors. SpringerPlus, 3, 2014, 535.
38. [38] Chia, S.K., Speers, C.H., D'yachkova, Y., Kang, A., Malfair-Taylor, S., Barnett, J., et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110:5 (2007), 973–979.